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INTRODUCTION 
Multiple sclerosis (MS) is the most common disabling 
neurological condition affecting young adults, and the 
prevalence of the disease in Canada, at 240 per 100000, is one 
of the highest in the world [1]. Neuronal degeneration is 
thought to contribute to progression in multiple sclerosis 
(MS). Iron accumulation in the central nervous system (CNS) 
of MS patients may lead to neuronal degeneration, partly by 
enhancing oxidative stress [2]. Women with MS tend to have 
fewer clinical relapses during pregnancy [3]. Minocycline, a 
tetracycline antibiotic with neuroprotective properties, has 
garnered interest in the treatment of MS [4]. Based on these 
observations, we hypothesized that pregnancy-associated 
hormones and minocycline would protect against iron 
neurotoxicity.  
METHODS 
Primary human foetal neuronal cultures were plated at 
100,000 cell/well in 96-well plates and pretreated with ß-
estradiol, progesterone, prolactin, allopregnanolone, and 
several tetracycline antibiotics for 24 hours (n=4). Cultures 
were then exposed to a 24-hour FeSO4 challenge, after which 
they were fixed with 4% paraformaldehyde. 
Immunocytochemistry was used to mark microtubule 
associated protein-2 (MAP-2), a neuronal marker in culture. 
MAP-2 positive neurons were quantified objectively using 
ImageXpress Micro.  
 
RESULTS 
24-hour exposure to FeSO4 resulted in significant, 
concentration-dependent loss of MAP-2 positive neurons. Pre-
treatment with progesterone and minocycline preserved the 
number of MAP-2 positive neurons compared to FeSO4 alone. 
Protection by minocycline was dependent on its co-presence 
with iron, suggesting a chemical interaction that may include 
alleviating oxidative stress; removing minocycline prior to 
iron exposure negated the protection. The effect of 
minocycline was compared to that of four other tetracycline 
antibiotics (tetracycline, oxycycline, doxycycline, 
demeclocycline), and only minocycline resulted in a 
preservation of MAP-2 positive neurons compared to iron alone. At 
the concentrations investigated, none of the pregnancy 
hormones examined (i.e. progesterone, ß-estradiol, estriol and 
allopregnanolone at 300ng/mL and prolactin at 30nM) were 
protective against iron.  
 
Figure 1. Mean number of MAP-2 positive neurons present in 
each treatment group (+SEM; n=4). Minocycline 
concentration is 10µg/mL, and Fe2+ is a 25µM FeSO4 
challenge. Both minocycline pre-treatment and Fe2+ challenge 
times were 24 hours. In the “wash” group, contents of the 
wells were removed before addition of the next treatment. 
Data were analyzed using a one-way ANOVA followed by the 
Bonferroni post-hoc test. ***p>0.001.  
DISCUSSION AND CONCLUSIONS 
The accumulation of iron in the CNS of MS can have 
neurotoxic outcomes.  This results of this experiment showed 
that minocycline can protect against the neurotoxicity of iron, 
possibly through a mechanism involving chemical interaction 
that could include countering oxidative stress. Since 
minocycline is being investigated in the treatment of MS [4], 
these results may bode well for its therapeutic efficacy. 
Furthermore, these findings may aid in development of 
treatments to reduce neurodegeneration in MS and other 
conditions involving iron accumulation and neurotoxicity.  
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